The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 107, Issue , 2016, Pages 110-119

  Donadei, Agnese ^a   Balocchi, Cristiana ^a   Mancini, Francesca ^a   Proietti, Daniela ^a   Gallorini, Simona ^a   O'Hagan, Derek T ^a   D'Oro, Ugo ^a   Berti, Francesco ^a   Baudner, Barbara C ^a   Adamo, Roberto ^a  

^a GSK   (Italy)

Author keywords

Adjuvants; Carbohydrate based vaccines; Glycoconjugates; Meningitidis; TLR7 agonist

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BACTERIAL POLYSACCHARIDE; DIPHTHERIA TOXOID CRM197; GLYCOCONJUGATE; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; MENC ANTIGEN; MENINGOCOCCAL SEROGROUP C GLYCOCOJUGATE VACCINE; MENINGOCOCCUS VACCINE; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; CRM197 (NON-TOXIC VARIANT OF DIPHTHERIA TOXIN); TLR7 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 7; VACCINE;

ADSORPTION; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PHYSICAL CHEMISTRY; AGONISTS; ANIMAL; CARBOHYDRATE ANALYSIS; CHEMISTRY; IMMUNOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL PROTEINS; CARBOHYDRATE SEQUENCE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GLYCOCONJUGATES; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS, SEROGROUP C; TOLL-LIKE RECEPTOR 7; VACCINES, CONJUGATE;

EID: 84977675373     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2016.07.004     Document Type: Article

References (48)

1. [1] Kasturi, S.P., Skountzou, I., Albrecht, R., Koutsonanos, D., Hua, T., Nakaya, H.I., Ravindran, R., Stewart, S., Alam, M., Kwissa, M., Villinger, F., Murthy, N., Steel, J., Jacob, J., Hogan, R.J., García-Sastre, A., Compans, R., Pulendran, B., Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470 (2011), 543–547.
2. [2] Dudek, A.Z., Yunis, C., Harrison, L.I., Kumar, S., Hawkinson, R., Cooley, S., Vasilakos, J.P., Gorski, K.S., Miller, J.S., First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin. Cancer Res. 13 (2007), 7119–7125.
3. [3] Reitz, A.B., Goodman, M.G., Pope, B.L., Argentieri, D.C., Bell, S.C., Burr, L.E., Chourmouzis, E., Come, J., Goodman, J.H., Klaubert, D.H., Maryanoff, B.E., McDonnell, M.E., Rampulla, M.S., Schott, M.R., Chen, R., Small-molecule immunostimulants. Synthesis and activity of 7,8-disubstituted guanosines and structurally related compounds. J. Med. Chem. 37 (1994), 3561–3578.
4. [4] Kurimoto, A., Ogino, T., Ichii, S., Isobe, Y., Tobe, M., Ogita, H., Takaku, H., Sajiki, H., Hirota, K., Kawakami, H., Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. Bioorg. Med. Chem. 12 (2004), 1091–1099.
5. [5] Kurimoto, A., Hashimoto, K., Nakamura, T., Norimura, K., Ogita, H., Takaku, H., Bonnert, R., McInally, T., Wada, H., Isobe, Y., Synthesis and biological evaluation of 8-oxoadenine derivatives as tolllike receptor 7 agonists introducing the antedrug concept. J. Med. Chem. Biol. 53 (2010), 2964–2972.
6. [6] Chan, M., Hayashi, T., Kuy, C.S., Gray, C.S., Wu, C.C.N., Corr, M., Wrasidlo, W., Cottam, H.B., Dennis, A.C., Synthesis and immunological characterization of Toll-like receptor 7 agonistic conjugates. Bioconjugate Chem. 20 (2009), 1194–1200.
7. [7] Wu, C.C., Hayashi, T., Takabayashi, K., Sabet, M., Smee, D.F., Guiney, D.D., Cottam, H.B., Carson, D.A., Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc. Natl. Acad. Sci. USA 104 (2007), 3990–3995.
8. [8] Wu, T.Y.-H., Singh, M., Miller, A.T., De Gregorio, E., Doro, F., D'Oro, U., Skibinski, D.A.G., Mbow, M.L., Bufali, S., Herman, A.E., Cortez, A., Li, Y., Nayak, B.P., Tritto, E., Filippi, C.M., Otten, G.R., Brito, L.A., Monaci, E., Li, C., Aprea, S., Valentini, S., Calabrό, S., Laera, D., Brunelli, B., Caproni, E., Malyala, P., Panchal, R.G., Warren, T.K., Bavari, S., O'Hagan, D.T., Cooke, M.P., Valiante, N.M., Rational design of small molecules as vaccine adjuvants. Sci. Transl. Med., 6, 2014, 263ra160.
9. [9] Tomai, M.A., Vasilakos, J.P., TLR-7 and -8 agonists as vaccine adjuvants. Expert Rev. Vaccines 10 (2011), 405–407.
10. [10] Johnston, D., Bystryn, J.C., Topical imiquimod is a potent adjuvant to a weakly immunogenic protein prototype vaccine. Vaccine 24 (2006), 1958–1965.
11. [11] Othoro, C., Johnston, D., Lee, R., Soverow, J., Bystryn, J.-C., Nardin, E., Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-Like Receptor 7 agonist, Imiquimod. Infect. Immun. 77 (2009), 739–748.
12. [12] Knuefermann, P., Nemoto, S., Baumgarten, G., Misra, A., Sivasubramanian, N., Carabello, B.A., Vallejo, J.G., Cardiac inflammation and innate immunity in septic shock: is there a role for toll-like receptors?. Chest 121 (2002), 1329–1336.
13. [13] Pockros, P.J., Guyader, D., Patton, H., Tong, M.J., Wright, T., McHutchison, J.G., Meng, T.C., Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, doubleblind phase IIa studies. J. Hepatol. 47 (2007), 174–182.
14. [14] Sauder, D.N., Smith, M.H., Senta-McMillian, T., Soria, I., Meng, T.C., Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob. Agents Chemother. 47 (2003), 3846–3852.
15. [15] Shinchi, H., Crain, B., Yao, S., Chan, M., Zhang, S.S., Ahmadiiveli, A., Suda, Y., Hayashi, T., Cottam, H.B., Carson, D.A., Enhancement of the immunostimulatory activity of a TLR7 ligand by conjugation to polysaccharides. Bioconjugate Chem. 25 (2015), 1713–1723.
16. [16] Nishiya, T., DeFranco, A.L., Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J. Biol. Chem. 279 (2004), 19008–19017.
17. [17] Russo, C., Cornella-Taracido, I., Galli-Stampino, L., Jain, R., Harrington, E., Isome, Y., Tavarini, S., Sammicheli, C., Nuti, S., Mbow, M.L., Valiante, N.M., Tallarico, J., De Gregorio, E., Soldaini, E., Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells. Blood 127 (2013), 5683–5691.
18. [18] Amorji, J.P., Kersten, G.F., Saluja, V., Tonnis, W.F., Hinrichs, W.L., Slütter, B., Bal, S.M., Bouwstra, J.A., Huckriede, A., Jiskoot, W., Towards tailored vaccine delivery: needs, challenges and perspectives. J. Control. Release 20 (2012), 363–376.
19. [19] Johnston, D., Zaidi, B., Bystryn, J.C., TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol. Immunother. 56 (2007), 1133–1141.
20. [20] Wille-Reece, U., Flynn, B.J., Lore, K., Koup, R.A., Kedl, R.M., Mattapallil, J.J., Weiss, W.R., Roederer, M., Seder, R.A., HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. USA 102 (2005), 15190–15194.
21. [21] Wille-Reece, U., Wu, C., Flynn, B., Kedl, R., Seder, R., Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 gag-specific Th1 and CD8 T cell responses. J. Immunol., 2005, 7676–7683.
22. [22] Oh, J.Z., Kedl, R.M., The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J. Immunol. 185 (2010), 4602–4608.
23. [23] Vecchi, S., Bufali, S., Uno, T., Wub, T., Arcidiacono, L., Filippini, S., Rigat, F., O'Hagan, D., Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model. Eur. J. Pharm. Biopharm. 87 (2014), 310–317.
24. [24] Pace, D., Glycoconjugate vaccines. Expert Opin. Biol. Ther. 13 (2013), 11–33.
25. [25] Berti, F., Adamo, R., Recent mechanistic insights on glycoconjugate vaccines and future perspectives. ACS Chem. Biol. 8 (2013), 1653–1663.
26. [26] Cohn, A.C., MacNeil, J.R., Harrison, L.H., Hatcher, C., Theodore, J., Schmidt, M., Pondo, T., Arnold, K.E., Baumbach, J., Bennett, N., Craig, A.S., Farley, Monica, Gershman, K., Petit, S., Lynfield, R., Reingold, A., Schaffner, W., Shutt, K.A., Zell, E.R., Mayer, L.W., Clark, T., Stephens, D., Messonnier, N.E., Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin. Infect. Dis. 50 (2010), 184–191.
27. [27] Barroso, D.E., Castiñeiras, T.M.P.P., Freitas, F.S., Marsh, J.W., Krauland, M.G., Tulenko, M.M., Fonseca, É.L., Vicente, A.C.P., Rebelo, M.C., Cerqueira, E.O., Xavier, A.C., Cardozo, A.P.C.M., da Silva, S.E.M., Harrison, L.H., Three outbreakcausing Neisseria meningitidis serogroup C clones, Brazil. Emerg. Infect. Dis. 19 (2013), 1847–1850.
28. [28] http://www.cdc.gov/meningococcal/surveillance/index.html.
29. [29] Costantino, P., Rappuoli, R., Berti, F., The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opin. Drug Disc. 6 (2011), 1045–1067.
30. [30] Adamo, R., Nilo, A., Harfouche, C., Brogioni, B., Pecetta, S., Brogioni, G., Balducci, E., Pinto, V., Sara, F., Mori, E., Tontini, M., Romano, M.R., Costantino, P., Berti, F., Investigating the immunodominance of carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C meningococcal disease. Glycocon. J. 31 (2014), 637–647.
31. [31] Johnson, R.J., Chenoweth, D.E., Labeling the granulocyte C5a receptor with a unique photoreactive probe. J. Biol. Chem. 260 (1985), 7161–7164.
32. [32] Bardotti, A., Berti, F., Berti, S., Carinci, V., D'Ascenzi, S., Fabbri, B., Giannini, S., Giannozzi, A., Magagnoli, C., Proietti, D., Norelli, F., Rappuoli, R., Ricci, S., Costantino, P., Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases. Vaccine 26 (2009), 2284–2296.
33. [33] Vecchi, S., Bufali, S., Skibinski, D.A.G., O'Hagan, D.T., Singh, M., Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations. J. Pharm. Sc. 101 (2012), 17–20.
34. [34] Giuliani, M.M., Santini, L., Brunelli, B., Biolchi, A., Aricò, B., Di Marcello, F., Cartocci, E., Masignani, C.M.V., Lozzi, L., Savino, S., Scarselli, M., Rappuoli, R., Pizza, M., The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect. Imm. 73 (2005), 1151–1160.
35. [35] Costantino, P., Viti, S., Podda, A.M., Velmonte, A., Nencioni, L., Rappuoli, R., Development and phase I clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10 (1992), 691–698.
36. [36] Crotti, S., Zhai, H., Zhou, J., Allan, M., Proietti, D., Pansegrau, W., Hu, Q.-Y., Berti, F., Adamo, R., Defined conjugation of glycans to the lysines of CRM197 guided by their reactivity mapping. ChemBioChem 14 (2014), 836–843.
37. [37] Otero, M., Calarota, S.A., Felber, B., Laddy, D., Pavlakis, G., Boyer, J.D., Weiner, D.B., Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine 22 (2004), 1782–1790.
38. [38] Weeratna, R.D., Makinen, S.R., McCluskie, M.J., Davis, H.L., TLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848). Vaccine 23 (2005), 5263–5270.
39. [39] Dillon, S., Agrawal, A., Van Dyke, T., Mccauley, L., Koh, A., Maliszewski, C., Akira, S., Pulendran, B., A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signalregulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J. Immunol. 172 (2004), 4733–4743.
40. [40] Rostamian, M., Sohrabi, S., Kavosifard, H., Niknam, H.M., Lower levels of IgG1 in comparison with IgG2a are associated with protective immunity against Leishmania tropica infection in BALB/c mice. J. Microbiol. Immunol. Infect., 14, 2015.
41. [41] Huber, V.C., McKeon, R.M., Brackin, M.N., Miller, L.A., Keating, R., Brown, S.A., Makarova, N., Perez, D.R., MacDonald, G.H., McCullers, J.A., Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vacc. Immunol. 13 (2006), 981–990.
42. [42] McKee, A.S., Munks, M.W., MacLeod, M.K.L., Fleenor, C.J., Van Rooijen, N., Kappler, J.W., Marrack, P., Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J. Immunol. 183 (2009), 4403–4414.
43. [43] Michaelsen, T.E., Kolberg, J., Aase, A., Herstad, T.K., Høiby, E.A., The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis. Scand. J. Immunol. 59 (2004), 34–39.
44. [44] Campbell, H., Andrews, N., Borrow, R., Trotter, C., Miller, E., Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin. Vaccine Immunol. 17 (2010), 840–847.
45. [45] Hirve, S., Bavdekar, A., Pandit, A., Juvekar, S., Patil, M., Preziosi, M.-P., Tang, Y., Marchetti, E., Martellet, L., Findlow, H., Elie, C., Parulekar, V., Plikaytis, B., Borrow, R., Carlone, G., Kulkarni, P.S., Goel, A., Suresh, K., Beri, S., Kapre, S., Jadhav, S., Preaud, J.-M., Viviani, S., LaForce, F.M., Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2–10 years: a phase II/III double-blind randomized controlled trial. Vaccine 30 (2012), 6456–6460.
46. [46] Vogelbruch, M., Nuss, B., Körner, M., Kapp, A., Kiehl, P., Bohm, W., Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy 55 (2000), 883–887.
47. [47] Partidos, C.D., Antigens onto bare skin: a ‘painless’ paradigm shift in vaccine deliver. Expert Opin. Biol. Ther. 3 (2003), 895–902.
48. [48] DeMuth, P.C., Li, A.V., Abbink, P., Liu, J., Li, H., Stanley, K.A., Smith, K.M., Lavine, C.L., Seaman, M.S., Kramer, J.A., Miller, A.D., Abraham, W., Suh, H., Elkhader, J., Hammond, P.T., Barouch, D.H., Irvine, D.J., Vaccine delivery with microneedle skin patches in nonhuman primates. Nat. Biotechnol. 31 (2013), 1082–1085.